



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/766,760	01/27/2004	Michael L. Klein	899-76335-02	2895
24197	7590	05/18/2007		
KLARQUIST SPARKMAN, LLP			EXAMINER	
121 SW SALMON STREET			BABIC, CHRISTOPHER M	
SUITE 1600				
PORLTAND, OR 97204			ART UNIT	PAPER NUMBER
			1637	
			MAIL DATE	DELIVERY MODE
			05/18/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Interview Summary	Application No.	Applicant(s)
	10/766,760	KLEIN ET AL.
	Examiner Christopher M. Babic	Art Unit 1637

All participants (applicant, applicant's representative, PTO personnel):

(1) Christopher M. Babic. (3) _____.

(2) Susan Alpert Siegel. (4) _____.

Date of Interview: 03 May 2007.

Type: a) Telephonic b) Video Conference
c) Personal [copy given to: 1) applicant 2) applicant's representative]

Exhibit shown or demonstration conducted: d) Yes e) No.
If Yes, brief description: _____.

Claim(s) discussed: 7, 16, and 17.

Identification of prior art discussed: _____.

Agreement with respect to the claims f) was reached. g) was not reached. h) N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: See Continuation Sheet.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN A NON-EXTENDABLE PERIOD OF THE LONGER OF ONE MONTH OR THIRTY DAYS FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.



Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.

Examiner's signature, if required

Continuation of Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: Applicant's representative proposed amending the claim language of claims 7, 16, and 17 to reflect the FIBL-6 mutation Gln->Arg at the amino acid position encoded by nucleotides 16,262, 16263, and 16,264 of the FIBL-6 gene, i.e. Gln5345Arg, to overcome the written description and scope of enablement rejections under USC 112, 1st paragraph. Applicant's representative further proposed amending the preambles of claims 16 and 17 to reflect methods of "confirming the diagnosis of macular degeneration" as opposed to a purely "diagnostic" method to overcome the enablement rejections under USC 112, 1st paragraph.